Psoriasis and Dry Skin: The Impact of Moisturizers

  • Joachim W. Fluhr
  • Enzo Berardesca
  • Razvigor Darlenski


In the dawn of twenty-first century, psoriasis is considered a chronic, systemic, inflammatory disease that affects skin and its appendages. Dermatology has entered the era of specific systemic treatments with biological therapeutic agents. On the other hand, emollients and moisturizers are still essential in the topical adjuvant treatment of psoriasis not only in the remission phase. They are excellent supplements to the classical and novel treatments and help to reduce the scale load of the individual patient. Their major role is to support the normalizing of hyperproliferation, differentiation and apoptosis. In addition, they exert anti-inflammatory effects, e.g. through physiological lipids. The improvement of epidermal barrier function and stratum corneum hydration makes the skin resistant to external stressors, causing the Köbner phenomenon in psoriasis.


Salicylic Acid Glycolic Acid Allergic Contact Dermatitis Plaque Psoriasis Psoriatic Lesion 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Seite S, Khemis A, Rougier A et al (2009) Emollient for maintenance therapy after topical corticotherapy in mild psoriasis. Exp Dermatol 18:1076–1078PubMedCrossRefGoogle Scholar
  2. 2.
    Murphy G, Reich K (2011) In touch with psoriasis: topical treatments and current guidelines. J Eur Acad Dermatol Venereol 25(Suppl 4):3–8PubMedCrossRefGoogle Scholar
  3. 3.
    Christopheres E, Mrowietz U (2003) Psoriasis. In: Freedberg IR, Eisen AZ, Wolff K et al (eds) Fitzpatrick’s dermatology in general medicine, McGraw-Hill Professional, New York City, USA, vol, 6th edn, pp 407–427Google Scholar
  4. 4.
    Zeichner JA, Lebwohl MG, Menter A et al (2010) Optimizing topical therapies for treating psoriasis: a consensus conference. Cutis 86:5–31; quiz 2PubMedGoogle Scholar
  5. 5.
    Guttman-Yassky E, Krueger JG (2007) Psoriasis: evolution of pathogenic concepts and new therapies through phases of translational research. Br J Dermatol 157:1103–1115PubMedCrossRefGoogle Scholar
  6. 6.
    Wippel-Slupetzky K, Stingl G (2009) Future perspectives in the treatment of psoriasis. Curr Probl Dermatol 38:172–189PubMedCrossRefGoogle Scholar
  7. 7.
    Witman PM (2001) Topical therapies for localized psoriasis. Mayo Clin Proc 76:943–949PubMedGoogle Scholar
  8. 8.
    Garcia-Valladares I, Cuchacovich R, Espinoza LR (2011) Comparative assessment of biologics in treatment of psoriasis: drug design and clinical effectiveness of ustekinumab. Drug Des Devel Ther 5:41–49PubMedGoogle Scholar
  9. 9.
    Greaves MW, Weinstein GD (1995) Treatment of psoriasis. N Engl J Med 332:581–588PubMedCrossRefGoogle Scholar
  10. 10.
    Schopf E, Mueller JM, Ostermann T (1995) Value of adjuvant basic therapy in chronic recurrent skin diseases. Neurodermatitis atopica/psoriasis vulgaris. Hautarzt 46:451–454PubMedCrossRefGoogle Scholar
  11. 11.
    Bikowski J (2001) The use of therapeutic moisturizers in various dermatologic disorders. Cutis 68:3–11PubMedGoogle Scholar
  12. 12.
    Brubacher JR, Hoffman RS (1996) Salicylism from topical salicylates: review of the literature. J Toxicol Clin Toxicol 34:431–436PubMedCrossRefGoogle Scholar
  13. 13.
    Nola I, Kostovic K, Kotrulja L et al (2003) The use of emollients as sophisticated therapy in dermatology. Acta Dermatovenerol Croat 11:80–87PubMedGoogle Scholar
  14. 14.
    Meyer N, Paul C, Feneron D et al (2010) Psoriasis: an epidemiological evaluation of disease burden in 590 patients. J Eur Acad Dermatol Venereol 24:1075–1082PubMedGoogle Scholar
  15. 15.
    Watsky KL, Freije L, Leneveu MC et al (1992) Water-in-oil emollients as steroid-sparing adjunctive therapy in the treatment of psoriasis. Cutis 50:383–386PubMedGoogle Scholar
  16. 16.
    Menter A, Korman NJ, Elmets CA et al (2009) Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol 60:643–659PubMedCrossRefGoogle Scholar
  17. 17.
    Comaish JS, Greener JS (1976) The inhibiting effect of soft paraffin on the Kobner response in psoriasis. Br J Dermatol 94:195–200PubMedCrossRefGoogle Scholar
  18. 18.
    Finlay AY (1997) Emollients as adjuvant therapy for psoriasis. J Dermatolog Treat 8(Suppl 1):S25–S27CrossRefGoogle Scholar
  19. 19.
    Cassano N, Mantegazza R, Battaglini S et al (2010) Adjuvant role of a new emollient cream in patients with palmar and/or plantar psoriasis: a pilot randomized open-label study. G Ital Dermatol Venereol 145:789–792PubMedGoogle Scholar
  20. 20.
    Tanghetti EA (2000) An observation study evaluating the treatment of plaque psoriasis with tazarotene gels, alone and with an emollient and/or corticosteroid. Cutis 66:4–11PubMedGoogle Scholar
  21. 21.
    Syed TA, Ahmad SA, Holt AH et al (1996) Management of psoriasis with Aloe vera extract in a hydrophilic cream: a placebo-controlled, double-blind study. Trop Med Int Health 1:505–509PubMedCrossRefGoogle Scholar
  22. 22.
    Paulsen E, Korsholm L, Brandrup F (2005) A double-blind, placebo-controlled study of a commercial Aloe vera gel in the treatment of slight to moderate psoriasis vulgaris. J Eur Acad Dermatol Venereol 19:326–331PubMedCrossRefGoogle Scholar
  23. 23.
    Held E, Sveinsdottir S, Agner T (1999) Effect of long-term use of moisturizer on skin hydration, barrier function and susceptibility to irritants. Acta Derm Venereol 79:49–51PubMedCrossRefGoogle Scholar
  24. 24.
    Gloor M, Hauth A, Gehring W (2003) O/W emulsions compromise the stratum corneum barrier and improve drug penetration. Pharmazie 58:709–715PubMedGoogle Scholar
  25. 25.
    Fluhr JW, Gloor M, Bettinger J et al (1998) On the influence of bath oils with different solvent characteristics and different amounts of a non-ionic tenside on the hydration and barrier function of the stratum corneum. J Cosmet Sci 49:343–350Google Scholar
  26. 26.
    Rim JH, Jo SJ, Park JY et al (2005) Electrical measurement of moisturizing effect on skin hydration and barrier function in psoriasis patients. Clin Exp Dermatol 30:409–413PubMedCrossRefGoogle Scholar
  27. 27.
    van Duijnhoven MW, Hagenberg R, Pasch MC et al (2005) Novel quantitative immunofluorescent technique reveals improvements in epidermal cell populations after mild treatment of psoriasis. Acta Derm Venereol 85:311–317PubMedGoogle Scholar
  28. 28.
    Penven K, Leroy D, Verneuil L et al (2005) Evaluation of Vaseline oil applied prior to UVB TL01 phototherapy in the treatment of psoriasis. Photodermatol Photoimmunol Photomed 21:138–141PubMedCrossRefGoogle Scholar
  29. 29.
    Birgin B, Fetil E, Ilknur T et al (2005) Effects of topical petrolatum and salicylic acid upon skin photoreaction to UVA. Eur J Dermatol 15:156–158PubMedGoogle Scholar
  30. 30.
    Fetil E, Ozka S, Soyal MC et al (2002) Effects of topical petrolatum and salicylic acid on the erythemogenicity of UVB. Eur J Dermatol 12:154–156PubMedGoogle Scholar
  31. 31.
    Draelos ZD (2008) Moisturizing cream ameliorates dryness and desquamation in participants not receiving topical psoriasis treatment. Cutis 82:211–216PubMedGoogle Scholar
  32. 32.
    Lebwohl M (1999) The role of salicylic acid in the treatment of psoriasis. Int J Dermatol 38:16–24PubMedCrossRefGoogle Scholar
  33. 33.
    Moncorps C (1929) Untersuchungen über die Pharmakologie und Pharmakodynamik von Salben und salbeninkorporierten Medikamenten II. Mitteilung: Über die Resorption und Pharmakodynamik der salbeninkorporiereten Salizylsäure. Arch Exp Path Pharm 155 (1–2): 51–69Google Scholar
  34. 34.
    Arnold W, Trinnes F, Schroeder I (1979) Skin resorption of salicylic acid in psoriasis patients and persons with healthy skin. Beitr Gerichtl Med 37:325–328PubMedGoogle Scholar
  35. 35.
    Gabard B, Treffel P, Schwarb F, Surber C, Bieli E, Lüdi S (1997) Salicylic acid release from topical formulations does not predict in vitro skin absorption. Dermatology 195:37–43Google Scholar
  36. 36.
    Schwarb F, Gabard B, Jost G, Rufli Th, Surber C (1997) Percutaneous absorption of salicylic acid in man following topical administration of different formulations. Dermatology 195Google Scholar
  37. 37.
    Weirich EG, Longauer JK, Kirkwood AH (1978) Effect of topical salicylic acid on animal epidermopoiesis. Dermatologica 156:89–96PubMedCrossRefGoogle Scholar
  38. 38.
    Pullmann H, Lennartz KJ, Steigleder GK (1975) The effect of salicylic acid on epidermal cell proliferation kinetics in psoriasis. Autoradiographic in vitro-investigations(author’s transl). Arch Dermatol Forsch 251:271–275PubMedCrossRefGoogle Scholar
  39. 39.
    Roberts DL, Marshall R, Marks R (1980) Detection of the action of salicylic acid on the normal stratum corneum. Br J Dermatol 103:191–196PubMedCrossRefGoogle Scholar
  40. 40.
    Davies M, Marks R (1976) Studies on the effect of salicylic acid on normal skin. Br J Dermatol 95:187–192PubMedCrossRefGoogle Scholar
  41. 41.
    Huber C, Christophers E (1977) “Keratolytic” effect of salicylic acid. Arch Dermatol Res 257:293–297PubMedCrossRefGoogle Scholar
  42. 42.
    Nook TH (1987) In vivo measurement of the keratolytic effect of salicylic acid in three ointment formulations. Br J Dermatol 117:243–245PubMedCrossRefGoogle Scholar
  43. 43.
    Gloor M, Beier B (1984) Keratoplastic effect of salicyclic acid, sulfur and a tensio-active mixture. Z Hautkr 59:1657–1660PubMedGoogle Scholar
  44. 44.
    Going SM, Guyer BM, Jarvie DR et al (1986) Salicylic acid gel for scalp psoriasis. Clin Exp Dermatol 11:260–262PubMedCrossRefGoogle Scholar
  45. 45.
    Hulsebosch HJ, Ponec-Waelsch M (1972) The interaction of anthralin, salicylic acid and zinc oxide in pastes. Dermatologica 144:287–293PubMedCrossRefGoogle Scholar
  46. 46.
    Runne U (1974) Anthralin-salicylic acid therapy of psoriasis. Cignolin-salicylic acid-vaseline treatment and Lasan paste in a right-left comparison. Hautarzt 25:199–200PubMedGoogle Scholar
  47. 47.
    Diem E, Fritsch P (1973) Salicylate poisoning by percutaneous resorption. Hautarzt 24:552–555PubMedGoogle Scholar
  48. 48.
    Zesch A (1986) Short and long-term risks of topical drugs. Br J Dermatol 115(Suppl 31):63–70PubMedCrossRefGoogle Scholar
  49. 49.
    Chapman BJ, Proudfoot AT (1989) Adult salicylate poisoning: deaths and outcome in patients with high plasma salicylate concentrations. Q J Med 72:699–707PubMedGoogle Scholar
  50. 50.
    Pec J, Strmenova M, Palencarova E et al (1992) Salicylate intoxication after use of topical salicylic acid ointment by a patient with psoriasis. Cutis 50:307–309PubMedGoogle Scholar
  51. 51.
    Luderschmidt C, Plewig G (1975) Chronic percutaneous salicylic acid poisoning. Hautarzt 26:643–646PubMedGoogle Scholar
  52. 52.
    Germann R, Schindera I, Kuch M et al (1996) Life threatening salicylate poisoning caused by percutaneous absorption in severe ichthyosis vulgaris. Hautarzt 47:624–627PubMedCrossRefGoogle Scholar
  53. 53.
    Vonweiss JF, Lever WF (1964) Percutaneous salicylic acid intoxication in psoriasis. Arch Dermatol 90:614–619PubMedCrossRefGoogle Scholar
  54. 54.
    Taylor JR, Halprin KM (1975) Percutaneous absorption of salicylic acid. Arch Dermatol 111:740–743PubMedCrossRefGoogle Scholar
  55. 55.
    van de Kerkhof PC, Vissers WH (2003) The topical treatment of psoriasis. Skin Pharmacol Appl Skin Physiol 16:69–83PubMedCrossRefGoogle Scholar
  56. 56.
    Waller JM, Dreher F, Behnam S et al (2006) ‘Keratolytic’ properties of benzoyl peroxide and retinoic acid resemble salicylic acid in man. Skin Pharmacol Physiol 19:283–289PubMedCrossRefGoogle Scholar
  57. 57.
    Bashir SJ, Dreher F, Chew AL et al (2005) Cutaneous bioassay of salicylic acid as a keratolytic. Int J Pharm 292:187–194PubMedCrossRefGoogle Scholar
  58. 58.
    Klimowicz A, Farfal S, Bielecka-Grzela S (2007) Evaluation of skin penetration of topically applied drugs in humans by cutaneous microdialysis: acyclovir vs. salicylic acid. J Clin Pharm Ther 32:143–148PubMedCrossRefGoogle Scholar
  59. 59.
    Klimowicz A, Bielecka-Grzela S, Groth L et al (2004) Use of an intraluminal guide wire in linear microdialysis probes: effect on recovery? Skin Res Technol 10:104–108PubMedCrossRefGoogle Scholar
  60. 60.
    Loden M (1996) Urea-containing moisturizers influence barrier properties of normal skin. Arch Dermatol Res 288:103–107PubMedCrossRefGoogle Scholar
  61. 61.
    Loden M (1997) Barrier recovery and influence of irritant stimuli in skin treated with a moisturizing cream. Contact Dermatitis 36:256–260PubMedCrossRefGoogle Scholar
  62. 62.
    Treffel P, Gabard B (1995) Stratum corneum dynamic function measurements after moisturizer or irritant application. Arch Dermatol Res 287:474–479PubMedCrossRefGoogle Scholar
  63. 63.
    Bettinger J, Gloor M, Gehring W, Wolf W (1995) Influence of emulsions with and without urea an water-binding capacity of the stratum corneum. J Soc Cosmet Chem 46:247–254Google Scholar
  64. 64.
    Muller KH, Pflugshaupt C (1989) Urea in dermatology I. Hautarzt 40(Suppl 9):1–12PubMedCrossRefGoogle Scholar
  65. 65.
    Wohlrab W (1988) Effect of urea on the water binding capacity of the human stratum corneum. Dermatol Monatsschr 174:622–627PubMedGoogle Scholar
  66. 66.
    Fluhr JW, Vrzak G, Gloor M (1998) Hydratisierende und die Steroidpenetration verbessernder Effekt von Harnstoff und Glycerin in Abhänigkeit von der verwendeten Grundlage. Z Hautkr 73:55–59Google Scholar
  67. 67.
    Wohlrab W, Schiemann S (1976) Investigations on the mechanism of the activity of urea upon the epidermis (author’s transl). Arch Dermatol Res 255:23–30PubMedCrossRefGoogle Scholar
  68. 68.
    Wohlrab W (1992) Harnstoff-ein bewährter Wirkstoff in der Dermatologie und Kosmetik. P Z 33:2483–2489Google Scholar
  69. 69.
    Wohlrab W (1986) Recovery rate of externally administered glucocorticoids on the skin surface. Dermatol Monatsschr 172:615–619PubMedGoogle Scholar
  70. 70.
    Feldmann RJ, Maibach HI (1974) Percutaneous penetration of hydrocortisone with urea. Arch Dermatol 109:58–59PubMedCrossRefGoogle Scholar
  71. 71.
    Wohlrab W (1984) The influence of urea on the penetration kinetics of topically applied corticosteroids. Acta Derm Venereol 64:233–238PubMedGoogle Scholar
  72. 72.
    Stuttgen G (1989) Promoting penetration of locally applied substances by urea. Hautarzt 40(Suppl 9):27–31PubMedCrossRefGoogle Scholar
  73. 73.
    Gloor M, Lindemann J (1980) The influence of ceratolytics and moisturizers on the bio-availability of triamcinolone acetonide following topical application (author’s transl). Dermatol Monatsschr 166:102–106PubMedGoogle Scholar
  74. 74.
    Kalbitz J, Neubert R, Wohlrab W (1996) Modulation of drug penetration in the skin. Pharmazie 51:619–637PubMedGoogle Scholar
  75. 75.
    Fluhr JW, Gloor M, Gehring W (2000) Physiology of Skin cleaning and functional mechanism of bath oils. In: Berardesca E, Picardo M, Pigatto P (eds) Irritant contact dermatitis – proceedings of the 3 rd International Symposium (ISICD). Medical Publishing & New Media, Milano, pp 291–307Google Scholar
  76. 76.
    Müller KH, Pflugshaupt Ch (1979) Harnstoff in der Dermatologie. Zbl Haut 1:14–15Google Scholar
  77. 77.
    Gabard B, Bieli E (1989) Salicylic acid and urea–possible modification of the keratolytic effect of salicylic acid by urea. Hautarzt 40(Suppl 9):71–73PubMedCrossRefGoogle Scholar
  78. 78.
    Hagemann I, Proksch E (1996) Topical treatment by urea reduces epidermal hyperproliferation and induces differentiation in psoriasis. Acta Derm Venereol 76:353–356PubMedGoogle Scholar
  79. 79.
    Sasaki Y, Tadaki T, Tagami H (1989) The effects of a topical application of urea cream on the function of pathological stratum corneum. Acta Dermatol – Kyoto 84:31Google Scholar
  80. 80.
    Shemer A, Nathansohn N, Kaplan B et al (2000) Treatment of scalp seborrheic dermatitis and psoriasis with an ointment of 40% urea and 1% bifonazole. Int J Dermatol 39:532–534PubMedCrossRefGoogle Scholar
  81. 81.
    Gloor M, Fluhr J, Wasik B et al (2001) Clinical effect of salicylic acid and high dose urea applied according to the standardized New German Formulary. Pharmazie 56:810–814PubMedGoogle Scholar
  82. 82.
    Hardening CR, Watkinson A, Rawlings AV, Scott IR (2000) Dry skin, moisturization and corneodesmolysis. Int J Cosmet Sci 22:21–52CrossRefGoogle Scholar
  83. 83.
    Lynde CW (2001) Moisturizers: what they are and how they work. Skin Therapy Lett 6:3–5PubMedGoogle Scholar
  84. 84.
    Kostarelos K, Teknetzis A, Lefaki I et al (2000) Double-blind clinical study reveals synergistic action between alpha-hydroxy acid and betamethasone lotions towards topical treatment of scalp psoriasis. J Eur Acad Dermatol Venereol 14:5–9PubMedCrossRefGoogle Scholar
  85. 85.
    Berardesca E, Piero Vignoli G, Distante E (1998) Effects of glycolic acid on psoriasis. Clin Exp Dermatol 23:190–191PubMedCrossRefGoogle Scholar
  86. 86.
    Escobar SO, Achenbach R, Iannantuono R et al (1992) Topical fish oil in psoriasis – a controlled and blind study. Clin Exp Dermatol 17:159–162PubMedCrossRefGoogle Scholar
  87. 87.
    Dewsbury CE, Graham P, Darley CR (1989) Topical eicosapentaenoic acid (EPA) in the treatment of psoriasis. Br J Dermatol 120:581PubMedCrossRefGoogle Scholar
  88. 88.
    Kragballe K, Voorhees P, Darley CR, Goetzl EJ (1985) Leukotriene B5 derived from eicosapentaenoic acid does not stimulate DNA synthesis of cultured human keratinocytes but inhibits the stimulation induced by leukotriene B4. J Invest Dermatol 84:349Google Scholar
  89. 89.
    Williams ML (1991) Lipids in normal and pathological desquamation. Adv Lipid Res 24:211–262PubMedGoogle Scholar
  90. 90.
    Berardesca E, Borroni G (1998) Oral and topical supplementation of linoleic acid and skin disease. Medecine, Biologie, Environnement 26(2):159–163Google Scholar
  91. 91.
    Henneicke-von Zepelin HH, Mrowietz U, Farber L et al (1993) Highly purified omega-3-polyunsaturated fatty acids for topical treatment of psoriasis. Results of a double-blind, placebo-controlled multicentre study. Br J Dermatol 129:713–717PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • Joachim W. Fluhr
    • 1
  • Enzo Berardesca
    • 2
  • Razvigor Darlenski
    • 3
  1. 1.Department of Dermatology, Venereology and AllergologyCharité - Universitätsmedizin BerlinBerlinGermany
  2. 2.San Gallicano Dermatological InstituteRomeItaly
  3. 3.Department of Dermatology and VenereologyTokuda Hospital SofiaSofiaBulgaria

Personalised recommendations